Choksi Laboratories Ltd (CHOKSILA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Choksi Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Intimation under Regulation 30 is attached herewith.
Others (Uncategorized) · 03 Nov 2026, 11:12 pm
Choksi Laboratories Receives USFDA EIR for Central Laboratory in Indore Choksi Laboratories Limited received an Establishment Inspection Report (EIR) from the USFDA on 3rd Nov'26, marking the formal closure of its inspection. The regulatory audit was previously conducted between 17th Aug'26 and 20th Aug'26 at the company's central laboratory facility located in Indore, Madhya Pradesh.
We are enclosing herewith clarification on delay in submission with respect to proceedings of EGM
Extra Ordinary General Meeting · 22 Oct 2026, 12:11 am
Choksi Laboratories Clarifies Delayed Filing of EGM Proceedings on Convertible Warrants Issue Choksi Laboratories clarified to BSE on 21st Oct'26 regarding the inadvertent submission delay of its Extra-Ordinary General Meeting (EGM) proceedings held on 17th Oct'26. The initial filing was made on 18th Oct'26 due to technical issues. The EGM considered shareholder approval for the issuance of convertible warrants on a preferential basis via a Special Resolution. Promoters and proposed allottees abstained from voting on the resolution. Remote e-voting was conducted from 14th Oct'26 to 16th Oct'26, with final scrutinizer results to follow.
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding non approval of proposed preferential issue of convertible warrants and request for closure of application for ....
Others (Uncategorized) · 19 Oct 2026, 6:24 pm
Choksi Laboratories Shareholders Reject Proposed Preferential Issue of Convertible Warrants Shareholders of Choksi Laboratories rejected the proposal for a preferential issue of convertible warrants during the Extraordinary General Meeting held on 17th Oct'26. Promoters and proposed allottees abstained from voting on the resolution. Consequently, the company will not proceed with the issuance and has requested BSE Limited to close its application for in-principle approval regarding the proposed preferential issue.
The voting result along with the scrutinizer report the e-voting and remote e-voting held at EGM of the company held on 17.10.2026.
Extra Ordinary General Meeting · 19 Oct 2026, 6:07 pm
Choksi Laboratories Shareholders Reject Preferential Warrant Issue to Promoters Choksi Laboratories Limited announced that shareholders rejected a special resolution to issue and allot convertible warrants on a preferential basis to the promoter and promoter group at its EGM held on 17th Oct'26. With interested promoters holding 2,192,754 shares abstaining, total votes polled stood at 1,317,555 (18.92% of outstanding shares). The proposal faced overwhelming opposition, securing only 7,088 votes in favor (0.54%) versus 1,310,467 votes against (99.46%), failing to achieve the requisite majority.
Summary of proceedings of EGM enclosed herewith
Extra Ordinary General Meeting · 18 Oct 2026, 4:22 pm
Choksi Laboratories Conducts EGM for Preferential Issue of Convertible Warrants Choksi Laboratories held an Extra Ordinary General Meeting on 17th Oct'26 to seek shareholder approval via special resolution for the issuance of convertible warrants on a preferential basis. Remote e-voting was conducted from 14th Oct'26 to 16th Oct'26 with a cut-off date of 10th Oct'26. Promoters and proposed allottees abstained from voting on the resolution. Final consolidated voting results from the scrutinizer will be declared and submitted to the stock exchange within 48 hours.
Extra-Ordinary General Meeting of the company is scheduled to be held on Saturday, 17th October, 2026 at 12:30 p.m. through video conferencing/OAVM to transact the business as set out in ....
Extra Ordinary General Meeting · 24 Sept 2026, 11:02 pm
Choksi Laboratories Proposes Preferential Warrant Issue of Rs. 6.2 Crore to Promoters Choksi Laboratories will hold an EGM on 17th Oct'26 to seek shareholder approval for issuing up to 3,50,000 convertible warrants on a preferential basis to promoters at Rs. 177 per warrant, aggregating Rs. 6.195 cr. Each warrant converts into one equity share within 18 months, with 25% payable upfront. Post-conversion, promoter shareholding will rise from 31.48% to 34.76%, representing 4.78% of the post-issue diluted equity capital. Remote e-voting runs from 14th Oct'26 to 16th Oct'26, with the cut-off date set as 10th Oct'26.
Board of Director in the board meeting dated 19.09.2026 has approved the issuance and allotment of warrants convertible into shares to promoter subject to approval from shareholders.
Others (Uncategorized) · 19 Sept 2026, 11:29 pm
Choksi Laboratories Board Approves ₹6.20 Crore Preferential Warrant Issue to Promoters Choksi Laboratories' board approved the preferential issuance of up to 3,50,000 convertible equity warrants at Rs. 177 per warrant, aggregating to Rs. 6.195 crore, to promoter group entities (Sunil Choksi, Himika Choksi, and Stela Choksi). Each warrant is convertible into one equity share (face value Rs. 10) within 18 months, requiring 25% upfront subscription payment. Post-conversion, promoter holdings will increase, with Sunil Choksi rising from 7.51% to 9.89%. The issue is subject to shareholder approval at an EGM scheduled for 17th Oct'26.
The voting result along with scrutinizer report for the AGM held on 18.09.2026
Annual General Meeting · 19 Sept 2026, 10:46 pm
1. Issuance and allotment of upto 3,50,000 (Three Lakh Fifty Thousand) warrants, fully convertible into one fully paid-up equity share of the Company to the Persons belonging to Promoter ....
Outcome · 19 Sept 2026, 9:47 pm
Choksi Laboratories Approves ₹6.20 Crore Preferential Warrant Issue to Promoters Choksi Laboratories' board approved the preferential issuance of up to 3,50,000 convertible equity warrants at Rs. 177 per warrant, aggregating up to Rs. 6.195 crore to promoter group members Sunil Choksi (2,00,000), Himika Choksi (1,00,000), and Stela Choksi (50,000). The issue requires 25% upfront subscription, with the 75% balance payable upon exercise within 18 months. Fully diluted promoter holding will rise accordingly, subject to shareholder approval at the EGM scheduled for 17th Oct'26.
Proceedings of the 33rd Annual General Meeting held on 18.09.2026
Annual General Meeting · 18 Sept 2026, 8:37 pm
Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/09/2026 ,inter alia, to consider and approve 1. To consider and approve ....
Intimation · 15 Sept 2026, 12:30 am
Choksi Laboratories Board to Consider Fundraising via Equity or Convertible Securities Choksi Laboratories Limited has scheduled a Board of Directors meeting on 19th Sep'26 to evaluate and approve a proposal for raising funds. The capital raise may occur through the issuance of equity shares, equity-linked instruments, or convertible securities, including warrants, via preferential issue or other permissible modes. The proposed transaction remains subject to necessary approvals from company shareholders as well as relevant statutory and regulatory authorities.
Submission of intimation for dispatch of letter regarding notice of upcoming AGM to those shareholders whose email addresses are not registered with the company/RTA or depositories
Annual General Meeting · 27 Aug 2026, 6:21 pm
Submission of Annual Report for the F.Y. 2025-26
Others (Uncategorized) · 26 Aug 2026, 12:34 am
Submission of Notice convening 33rd AGM of the company to be held on 18th September, 2026 at 12:30 p.m. through Video conference/Other Audio Visual means
Annual General Meeting · 26 Aug 2026, 12:27 am
Intimation under Regulation 30 of SEBI (LODR) 2015 for inspection of USFDA
Others (Uncategorized) · 21 Aug 2026, 10:39 pm
Choksi Laboratories Receives Four USFDA Observations at Indore Facility Choksi Laboratories' central laboratory in Indore was inspected by the USFDA between 17th Aug'26 and 20th Aug'26. The inspection concluded with the company receiving four observations. Management is addressing the issues comprehensively and will respond to the USFDA within the stipulated timeframe. The company reaffirmed its commitment to maintaining the highest standards of quality and regulatory compliance. The nature and severity of the observations were not disclosed. This development is a key monitorable for regulatory risk.
Reappointment of Internal Auditor for the F.Y. 2026-27
Change in Management · 13 Aug 2026, 10:58 pm
Choksi Laboratories Re-Appoints Internal Auditor for FY26-27 Choksi Laboratories has re-appointed M/s Tanmay V. Rajurkar & Co., a chartered accountant firm, as its Internal Auditor for the financial year 2026-27. The appointment, effective 13th Aug'26, is a routine measure to comply with regulatory requirements under the Companies Act, 2013, and SEBI (LODR) Regulations, 2015. M/s Tanmay V. Rajurkar & Co. has extensive experience in corporate taxation, audit, and legal matters. No relationships were disclosed between the auditor and the company's directors.
Reappointment of Ms. Himika Choksi as Whole Time Director for further period of five year w.e.f 01.04.2027 subject to approval from shareholders in the ensuing AGM.
Change in Management · 13 Aug 2026, 10:52 pm
Considered and approved the unaudited financial results of the company for the quarter ended 30th June. 2026
Financial Result · 13 Aug 2026, 8:57 pm
Choksi Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 1,208 (+7.4% YoY | -6.2% QoQ) ■ EBITDA: 330 (+13.6% YoY | -11.0% QoQ) ■ EBITDA Margin (%): 27.3 (+150 bps YoY | -145 bps QoQ) ■ PAT: 58.2 (+51.3% YoY | -43.3% QoQ) ■ EPS (INR): 0.84 (+52.7% YoY | -42.9% QoQ)
1. Considered and approved the Unaudited Financial Results for the Quarter ended on 30th June, 2026 along with the Limited review report; 2. Decided the date for closure of Register of ....
Outcome · 13 Aug 2026, 8:52 pm
Intimation for change of RTA in pursuant to Regulation 30 of SEBI (LODR) 2015
Others (Uncategorized) · 03 Aug 2026, 10:44 pm
Choksi Laboratories Appoints New Registrar and Share Transfer Agent Choksi Laboratories has changed its Registrar and Share Transfer Agent (RTA) from MUFG Intime India Private Limited to Ankit Consultancy Private Limited, effective 03 Aug'26. The decision was based on a comprehensive evaluation of service offerings, technological capabilities, and local convenience. The company has received confirmation of the RTA change for electronic connectivity from depositories NSDL and CDSL. A new tripartite agreement will be executed in due course as per regulatory requirements.
Result as attached
Financial Result · 25 May 2026, 10:09 pm
Choksi Laboratories Posts Strong Q4 and FY26 Results with Profit Growth Choksi Laboratories reported robust FY26 results with net profit rising 29.0% YoY to ₹196.43 lakhs and revenue from operations growing 10.1% YoY to ₹4600.59 lakhs. For Q4 FY26, net profit was ₹102.68 lakhs, up 11.5% YoY, on revenue of ₹1282.22 lakhs, up 12.5% YoY. The company recorded an exceptional gain of ₹75.30 lakhs in FY26 from the sale of a property. Basic EPS for FY26 stood at ₹2.82, compared to ₹2.19 in FY25. The results were approved on 25th May'26.
1. Considered and approved Audited Financial Results for the Quarter and Financial Year ended 31st March, 2026 along with the along with the Auditors Report thereon, Statement of Assets ....
Outcome · 25 May 2026, 9:54 pm
Choksi Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 1,288 (+12.6% YoY | +17.6% QoQ) ■ EBITDA: 371 (+4.6% YoY | +32.7% QoQ) ■ EBITDA Margin (%): 28.8 (-221 bps YoY | +329 bps QoQ) ■ PAT: 103 (+11.5% YoY | +230.8% QoQ) ■ EPS (INR): 1.47 (+11.4% YoY | +226.7% QoQ)
The clarification has been attached herewith in pursuant to additional details required for the corporate announcement filed under Regulation 30
Others (Uncategorized) · 19 May 2026, 11:23 pm
Choksi Laboratories Appoints New CFO and Changes Registrar Choksi Laboratories announced key decisions from its 18th May'26 board meeting. The board accepted the resignation of CFO Vyangesh Choksi, effective 18th May'26, and simultaneously appointed Mrs. Stela Choksi as the new Chief Financial Officer. Additionally, the company initiated the process to change its Registrar and Share Transfer Agent from MUFG Intime India Private Limited to Ankit Consultancy Private Limited. The board also reviewed the purchase of a vehicle for the company via a loan from HDFC Bank.
Intimation for appointment of Mrs. Stela Choksi as Chief Financial Officer of the company
Change in Management · 18 May 2026, 11:04 pm
Choksi Laboratories Appoints Mrs. Stela Choksi as Chief Financial Officer Choksi Laboratories has appointed Mrs. Stela Choksi as Chief Financial Officer, effective 18th May'26. A promoter member of the company, she brings diversified experience in finance and administration. Mrs. Choksi also serves as a Whole Time Director. She is the wife of Managing Director Mr. Sunil Choksi, and mother to Whole Time Directors Ms. Himika Choksi and Mr. Vyangesh Choksi. The Board has also authorized her to determine the materiality of information for disclosure to stock exchanges.
Intimation for resignation of Mr. Vyangesh Choksi as Chief Financial Officer of the company
Change in Management · 18 May 2026, 10:20 pm
Choksi Laboratories CFO Resigns to Focus on New Internal Projects Mr. Vyangesh Choksi has resigned from his position as Chief Financial Officer (CFO) of Choksi Laboratories, effective 18th May'26. He will continue to serve as a Whole Time Director for the company. The resignation is due to his commitment to multiple new ongoing projects within the company. Mr. Choksi confirmed there are no other material reasons for his departure. The company is now tasked with appointing a new CFO to lead its financial operations.